# A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

> **NCT05890287** · NA · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 60 (estimated)

## Conditions studied

- HR Positive HER2 Negative Advanced Breast Cancer

## Interventions

- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT05890287
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-16
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05890287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05890287, "A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05890287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*